Compare SUUN & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUUN | NSRX |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 52.5M |
| IPO Year | N/A | 2025 |
| Metric | SUUN | NSRX |
|---|---|---|
| Price | $1.22 | $5.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.00 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 2.9M | 4.6K |
| Earning Date | 02-13-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $32,753,484.00 | N/A |
| Revenue This Year | $127.67 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $4.90 |
| 52 Week High | $6.30 | $9.99 |
| Indicator | SUUN | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 41.46 |
| Support Level | $1.38 | $4.90 |
| Resistance Level | $1.96 | $6.30 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 3.25 | 40.49 |
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.